Vivus, Inc.: VVUS (NASDAQ)
2/13/2002 Princeton, New Jersey, (Bloomberg Data) -- Vivus Inc. (VVUS US) was rated new ``strong buy'' in new coverage by analyst Sheetal Patel at Roth Capital Partners.
1/25/2002 VVUS recommended in Business Week by Red Chip Review...
biz.yahoo.com
1/25/2002 C.E. Unterberg, Towbin reiterated their STRONG BUY RATING and a 12 month price target of $14 based on Vivus' better than anticipated earnings announcement, the strength of the clinical program (pipeline)and intellectual property position(s).
VIVUS goal is to establish a robust pipeline consisting of drug candidates at various stages of development, with a focus on innovative therapies intended to serve large and unsatisfied markets. In addition to the Companys currently marketed products, MUSE. and ACTIS., VIVUS is developing products for male erectile dysfunction, female sexual dysfunction, and premature ejaculation.
GO to WWW.VIVUS.COM for complete product pipeline information.
CONTACT: VIVUS Inc.
Richard Walliser, 650/934-5200
ir@vivus.com
www.vivus.com
or
Lippert/Heilshorn & Associates Inc.
Bruce Voss, 310/691-7100 (Investor Contacts)
bvoss@lhai.com
Jody Cain, 310/691-7100 (Investor Contacts)
jcain@lhai.com
Elissa Grabowski, 212/838-3777 (Media Contact)
egrabowski@lhai.com
www.lhai.com |
